DK0821955T3 - Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse - Google Patents

Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse

Info

Publication number
DK0821955T3
DK0821955T3 DK97305585T DK97305585T DK0821955T3 DK 0821955 T3 DK0821955 T3 DK 0821955T3 DK 97305585 T DK97305585 T DK 97305585T DK 97305585 T DK97305585 T DK 97305585T DK 0821955 T3 DK0821955 T3 DK 0821955T3
Authority
DK
Denmark
Prior art keywords
heoxyloxy
xanomelin
thiadiazol
methylpyridine
tetrahydro
Prior art date
Application number
DK97305585T
Other languages
Danish (da)
English (en)
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0821955T3 publication Critical patent/DK0821955T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
  • Processing Of Solid Wastes (AREA)
  • Press Drives And Press Lines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97305585T 1996-08-01 1997-07-25 Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse DK0821955T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2290096P 1996-08-01 1996-08-01

Publications (1)

Publication Number Publication Date
DK0821955T3 true DK0821955T3 (da) 2002-03-18

Family

ID=21812011

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97305585T DK0821955T3 (da) 1996-08-01 1997-07-25 Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse

Country Status (19)

Country Link
EP (1) EP0821955B1 (fr)
JP (1) JP2000515547A (fr)
KR (1) KR20000029647A (fr)
CN (1) CN1226165A (fr)
AT (1) ATE213413T1 (fr)
AU (1) AU716972B2 (fr)
BR (1) BR9710901A (fr)
CA (1) CA2261802C (fr)
CZ (1) CZ27299A3 (fr)
DE (1) DE69710526T2 (fr)
DK (1) DK0821955T3 (fr)
EA (1) EA199900174A1 (fr)
ES (1) ES2171838T3 (fr)
HU (1) HUP9904578A2 (fr)
IL (1) IL128280A0 (fr)
NO (1) NO990436D0 (fr)
PL (1) PL331407A1 (fr)
PT (1) PT821955E (fr)
WO (1) WO1998005324A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2742728T3 (es) * 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
CN111430027B (zh) * 2020-03-18 2023-04-28 浙江大学 基于肠道微生物的双相情感障碍生物标志物及其筛选应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
PT734259E (pt) * 1993-08-19 2002-11-29 Novo Nordisk As Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
CA2202776A1 (fr) * 1994-10-31 1996-05-09 Franklin Porter Bymaster Procede de traitement de l'angoisse

Also Published As

Publication number Publication date
NO990436L (no) 1999-01-29
EP0821955A2 (fr) 1998-02-04
ES2171838T3 (es) 2002-09-16
AU716972B2 (en) 2000-03-09
AU4046897A (en) 1998-02-25
PL331407A1 (en) 1999-07-19
EP0821955B1 (fr) 2002-02-20
WO1998005324A1 (fr) 1998-02-12
JP2000515547A (ja) 2000-11-21
CA2261802C (fr) 2006-11-07
DE69710526T2 (de) 2002-10-02
EP0821955A3 (fr) 1998-04-22
IL128280A0 (en) 1999-11-30
EA199900174A1 (ru) 1999-08-26
CA2261802A1 (fr) 1998-02-12
NO990436D0 (no) 1999-01-29
KR20000029647A (ko) 2000-05-25
ATE213413T1 (de) 2002-03-15
BR9710901A (pt) 1999-08-17
DE69710526D1 (de) 2002-03-28
PT821955E (pt) 2002-07-31
CN1226165A (zh) 1999-08-18
CZ27299A3 (cs) 1999-08-11
HUP9904578A2 (hu) 2000-06-28

Similar Documents

Publication Publication Date Title
ES2188095T3 (es) Carboxamidas heterociclicas.
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DK0627221T3 (da) Substans P antagonister til behandling af emesis
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
DE69725825D1 (de) 5-HT1F-Agonisten
DE69901717D1 (de) Phosphohalohydrine, verfahren zu deren herstellung und verwendungen
NO20014925D0 (no) Farmasöytiske forbindelser
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
DK0656209T3 (da) Melatoninderivater til anvendelse ved behandling af desynkroniseringsforstyrrelser
ATE213413T1 (de) Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen
ZA200203347B (en) Methods, kits and compositions for using pyrrole derivatives
EP0821957A3 (fr) Utilisation de la 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tétrahydro-1-méthylpyridine (xanoméline) pour traiter l'abus de drogues
MX9703363A (es) Nuevos derivados de pirimidiniloxi- y pirimidinilamino etilfenil-dioxolano.
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
DE69711506D1 (de) Methylsulfomycin 1, Verfahren zu dessen Herstellung und Verwendung
ES2141830T3 (es) Derivado de diester fosfonico.
DK0810223T3 (da) Adamantylsubstituerede oxindoler som farmaceutiske midler
DK1304107T3 (da) Anvendelse af oxozolidinonderivater til behandling af psoriasis
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose